Articles tagged with Vaccination
Researchers found a slightly increased rate of rare blood clots, including cerebral blood clots and venous blood clots, following AstraZeneca vaccination. The absolute risk remains low, but the vaccine has been removed from Danish and Norwegian vaccination programmes due to concerns.
A new case report details the treatment of a patient with VITT (vaccine-induced thrombotic thrombocytopenia) using bivalirudin, an alternative to heparin. Early outcomes suggest that this approach may be safe and effective in treating these rare but serious clot reactions.
A study found that users of conservative and social media were more likely to believe in COVID-19 conspiracies, with a significant increase in belief from March to July 2020. Mainstream news consumption was associated with decreased conspiracy beliefs.
The European Federation of Academies of Sciences and Humanities (ALLEA) releases a report calling for enhanced European exchange and coordination to tackle science disinformation. Key strategies include inoculation, debunking, fact-checking, and media literacy, as well as innovations in science communication.
A study by Imperial College London found that prior COVID-19 infection significantly enhances protection against the Kent and South Africa variants after a single dose of mRNA vaccine. In contrast, those without previous SARS-CoV-2 infection may not receive sufficient immune response, highlighting the importance of second doses.
A new paradigm for usability aims to address accessibility issues worldwide, with a focus on marginalized groups. The approach emphasizes the importance of user-centered design and its potential to drive improvements in various fields.
A high rate of vaccination is vital to reducing COVID-19 cases and controlling the pandemic, according to new research from the Mayo Clinic. If Minnesota had achieved a 75% vaccination rate by early April, case numbers and hospitalizations would plummet by July.
A recent study from the University of Virginia Health System found that more than a quarter of American infants in 2018 had not received all recommended childhood vaccines. Disparities were observed among African-American infants, low-income families, and those with lower education levels. The researchers warn that these gaps can lead ...
Experts warn that cerebral venous sinus thrombosis (CVST) blood clots are rare but serious events associated with COVID-19 infections, not vaccines. Immediate screening and non-heparin anticoagulants can help diagnose and treat the condition. Most patients can recover fully with proper treatment.
A Cornell-led research survey found that many Americans believe the Moderna and Pfizer-BioNTech vaccines provide weak protection against COVID-19 after a second dose. The study highlights the need for improved guidance on continued public health precautions, such as wearing masks, to combat vaccine attrition and prolong pandemic recovery.
A quality improvement study evaluated the length, readability, and complexity of COVID-19 vaccine phase III randomized clinical trial informed consent documents. The study found that these documents were often lengthy and complex, posing a barrier to participant understanding.
The article discusses the critical role of Texas Biomed in the development of the Pfizer COVID-19 vaccine through preclinical testing. Scientists tested two mRNA vaccine candidates in rhesus macaques, showing high effectiveness in protecting against SARS-CoV-2, and highlighting the importance of rapid therapy and vaccine development.
The study estimates that only about 24% of young adults aged 18 to 21 in the United States have been fully vaccinated against human papillomavirus (HPV). The low vaccination rate is a cause for concern given the significant health risks associated with HPV infection, including cervical cancer and other types of cancer.
Researchers analyzed COVID-19 vaccination data and found no significant association between mRNA vaccines and facial paralysis. The study suggests that compared to other viral vaccines, mRNA COVID-19 vaccines do not display a signal of facial paralysis.
The study found that 25.4% of vaccinated people experienced systemic side effects, with headache being the most common, while local side effects were reported by 66.2%.
A small study from Mayo Clinic researchers raises concerns that some transplant patients may have a limited immune response after receiving an mRNA COVID-19 vaccine. The study found that infected vaccinated solid organ transplant recipients had a 10 times higher infection rate compared to the general population.
Researchers are enrolling 500 participants, 400 with primary/secondary immune system disorders and 100 without, to study COVID-19 vaccine responses. The study aims to characterize features and adequacy of immune responses and provide valuable information about benefits and potential risks in individuals with immune deficiencies.
Recent polls of people aged 14 to 24 reveal most young people are taking COVID-19 seriously and motivated by a desire to protect others. They prioritize following public health guidance when near close contacts or in 'pod' situations.
A simulation modeling study estimates the benefits of identifying silent COVID-19 infections among children as a proxy for their vaccination. The study suggests that vaccination can significantly reduce future infection rates in this population.
A study from Rockefeller University suggests that breakthrough COVID cases may be driven by rapid evolution of the virus. Ongoing testing of immunized individuals is crucial to mitigate future outbreaks.
A $17 billion investment in NIH-funded research on vaccine technologies provided a foundation for the rapid development of COVID-19 vaccines. The study highlights the critical role of government-funded research in ensuring vaccine readiness.
A new study by Johns Hopkins Medicine researchers found that mRNA vaccines for COVID-19 may provide protection against the latest variant strains and even the common cold. The vaccine-induced T cell response was found to be effective in recognizing the spike proteins of both SARS-CoV-2 and three common cold coronaviruses.
Researchers at Northwestern University have discovered a new biomanufacturing platform that can increase protein-based vaccine yields by five-fold and reduce production costs to $1 per dose. The technology utilizes enriched cell-free extracts with cellular membranes, significantly broadening access to potentially lifesaving medicines.
The study found that the vaccine is highly effective across all age ranges, with 92% effectiveness in preventing symptomatic disease in individuals 70 years and older. Vaccine effectiveness varied among subpopulations, with slightly lower rates in multi-morbid populations and immunosuppressed individuals.
A synthetic DNA vaccine for MERS-CoV induced robust antibody neutralizing antibodies and cellular immune responses, protecting against MERS-CoV in NHP models. The low-dose regimen with intradermal delivery was more impactful in controlling disease than the higher dose delivered intramuscularly.
A study published in PLOS Biology suggests delaying the second dose of COVID-19 vaccines for 9-15 weeks after the first dose can avoid more hospitalizations, infections, and deaths. The researchers found that prioritizing widespread inoculation with available first doses is critical to mitigating adverse outcomes.
A new study published in Frontiers in Immunology suggests that the gut's immune response to COVID-19 infection may not provide long-lasting systemic immunity from the virus. The researchers found relatively few immune cells with a specific marker in the blood of patients with COVID-19, indicating limited protection for other organs.
Researchers identified serum amyloid A (SAA) as a potential biomarker for COVID-19 risk, with higher levels associated with increased inflammation, clot abnormalities, and organ damage. This biomarker could help facilitate early identification of patients requiring aggressive management and monitoring.
Research finds mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia and multiple myeloma. Patients with CLL who are treatment-naive or in remission tend to respond better to the vaccine.
A recent study published in Social Influence found that when people are explicitly told they are free to accept or reject propagandistic claims, their likelihood of choosing a moderate view increases. This approach, based on self-determination theory and psychological reactance theory, aims to disrupt the radicalization process among v...
A majority of 2,400 participants in a Penn State study supported requiring students and staff to be vaccinated against COVID-19. The survey found that Democrats were consistently more supportive of vaccine mandates than moderates or Republicans.
A new study from the University of Pennsylvania School of Medicine suggests that individuals who have recovered from COVID-19 may only need one vaccine dose to produce a sufficient antibody response. In contrast, those who have not had COVID-19 require two doses to achieve strong levels of immunity.
A Kaiser Permanente study found that child vaccination rates declined significantly during the COVID-19 pandemic, with measles vaccination coverage remaining substantially reduced in many age groups. The decline was more severe and persistent in older children, highlighting concerns about vaccine-preventable diseases.
A new vaccine for leishmaniasis has demonstrated safety and induced immune responses in patients with the disease. The vaccine, called ChAd63-KH, is being tested to determine its potential as a therapy for different forms of leishmaniasis.
Scientists have developed a method to create crystalline exoskeletons around delicate liposomes and lipid nanoparticles, stabilizing them at room temperature for up to two months. This breakthrough could help address the need for COVID-19 vaccines to be kept at below-freezing temperatures during transport and storage.
A recent survey of youth aged 14-24 found that most are willing to get vaccinated against COVID-19, with 75% unconditionally willing or already vaccinated. Black young people were more likely to express concerns about vaccine safety.
Experts argue that the Tokyo Olympics and Paralympics should not be held this summer due to ongoing COVID-19 concerns. They point out that vaccine roll-out has been inequitable, reducing access in many low-income countries, and that Japan's lack of control over community transmission poses a significant risk.
A new study found that individuals with negative attitudes towards vaccines and conspiracy suspicions are more likely to be hesitant about getting vaccinated against SARS-CoV-2. The research suggests that communication strategies must account for the polarising nature of conspiracy theories to increase vaccine compliance.
Author Michael Dahlstrom's paper examines how narratives or storytelling can help counter misinformation on vaccines by providing context and connection between facts. This approach recognizes the disproportionate influence of narratives on attitudes and behaviors, and highlights their potential as a tool for public health education.
Researchers from NIH propose a new method to estimate vaccine efficacy by following original placebo recipients after vaccination, allowing assessment of durability and potential delayed harm. This approach enables timely access to the vaccine for placebo recipients while maintaining unbiased estimates.
A surveillance project found high COVID-19 vaccine acceptance among physicians and advance practice providers, but lower rates among nurses and nonclinical healthcare workers. The authors suggest educating these groups about the vaccine's safety profile to enhance vaccination rates.
A recent study examines potential associations between COVID-19 vaccinations and functional neurological disorder, a condition characterized by symptoms similar to those experienced during a neurologic event. The researchers aim to better understand the relationships between vaccination and neurological side effects.
A new study from Aarhus University found that 89% of Danes are willing to be vaccinated against COVID-19, unchanged after the AstraZeneca vaccine was paused due to rare blood clots. The low level of confidence in the safety of the AstraZeneca vaccine is an important signal to health authorities.
A Canadian Medical Association Journal analysis found 75% of adults have at least one risk factor for severe COVID-19. The study suggests considering geographic and occupational risks to refine vaccination strategies and promote equity goals.
Experts recommend a more nuanced approach to COVID-19 vaccine prioritization, taking into account job site and neighborhood risks. At least 75% of Canadian adults have at least one risk factor for severe illness, highlighting the need for targeted vaccination strategies.
A survey study examines US adults' beliefs on who should be prioritized for access to COVID-19 vaccines. The study found that some groups, including young children and individuals with underlying health conditions, are more likely to be prioritized over others.
Functional neurological disorder (FND) is a disruption in the brain's normal mechanisms for controlling the body and can be triggered by physical or emotional events, including vaccinations. Individuals with FND may experience symptoms such as limb weakness, gait problems, jerky movements, tremor and facial spasms.
Beth Israel Deaconess Medical Center shares five key lessons on health equity from its COVID-19 vaccination campaign, including obtaining reliable patient data and addressing structural inequalities. The health system's approach aims to reach marginalized communities with trust-building strategies.
A new report confirms polyethylene glycol (PEG) as a cause of anaphylaxis following COVID-19 vaccination. The authors note that PEG allergy is rare and that COVID-19 vaccines remain safe despite the risk.
A USC study found Hispanic immigrants aged 20-54 are 11 times more likely to die from COVID-19 compared to U.S.-born non-Hispanic individuals. Younger populations, particularly those of Asian/Pacific Islander and Black descent, also face higher mortality rates.
The NIH is conducting a clinical trial to assess the risk of systemic allergic reactions to the Moderna and Pfizer-BioNTech COVID-19 vaccines in people with mast cell disorders or severe allergies. The study aims to identify potential genetic patterns that may predict who is at most risk for these reactions.
Patients with kidney failure undergoing hemodialysis developed a positive antibody response after COVID-19 vaccination, but at lower levels than healthy individuals. The findings highlight the need to reconsider vaccination schedules for this patient group.
A new model has been developed to estimate the risk of SARS-CoV-2-related death among patients in the Veterans Affairs health care system, enabling healthcare professionals to prioritize vaccination strategies.
Case report describes two patients who underwent a successful second dose of the Moderna vaccine using a graded dosing protocol after experiencing immediate hypersensitivity reactions. Both patients responded well and developed IgG antibodies, suggesting effective vaccination despite the modified dosing schedule.
A recent study found that a higher percentage of people in Appalachia are unlikely to receive the COVID-19 vaccine compared to national numbers. The researchers also tested interventions to stop the spread of misinformation, finding that subtle warnings from trusted health influencers can make a difference.
A study by Cedars-Sinai researchers found that individuals with prior COVID-19 infections who received a single dose of the Pfizer-BioNTech vaccine developed an antibody response similar to those without prior infection. The findings suggest that a single booster dose may be sufficient for previously infected individuals.
A UConn researcher has developed a successful Zika vaccine in preclinical studies using a novel platform technology. The vaccine, based on a viral vector and enhanced expression of the virus antigen, was found to mount a strong immune response and protect against Zika virus infection.
The NIH has started a Phase 1 clinical trial to evaluate the safety and immunogenicity of Moderna's COVID-19 variant vaccine, mRNA-1273.351, designed to protect against the B.1.351 SARS-CoV-2 variant. The trial enrolls approximately 210 healthy adult volunteers and aims to assess the reactogenicity and immune response of the vaccine.
Researchers developed a tamper-proof temperature indicator to monitor mRNA vaccine storage conditions. The system can alert healthcare workers when the vaccine reaches an unsafe temperature for a certain period, ensuring effective distribution and use of the vaccine.
A new mathematical model suggests that easing lockdown must be accompanied by wider and more effective use of control measures like facemasks to suppress COVID-19. The model shows that non-spatial control measures can limit virus particle spread between people.